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To develop a novel acute graft-versus-host disease (GVHD) risk score, we examined the GVHD clinical stage
and grade of 1723 patients at the onset of treatment with systemic steroids. Using clinical grouping,
descriptive statistics and recursive partitioning, we identiﬁed poorly responsive, high-risk (HR) acute GVHD
by the number of involved organs and severity of GVHD at onset. The overall response (complete response/
partial response) rate 28 days after initiation of steroid therapy for acute GVHD was lower in the 269 patients
with HR-GVHD than in the 1454 patients with standard risk (SR)-GVHD (44% [95% conﬁdence interval (CI)
38% to 50%] versus 68% [95% CI, 66% to 70%], P < .001). Patients with HR-GVHD were less likely to respond at
day 28 (odds ratio [OR], .3; 95% CI, .2 to .4; P < .001) and had higher risks of mortality (relative risk, 2.1; 95% CI,
1.7 to 2.6; P < .001) and transplant-related mortality (relative risk, 2.5; 95% CI, 2.0% to 3.2%, P < .001) than
patients with SR-GVHD. This reﬁned deﬁnition of acute GVHD risk is a better predictor of response, survival,
and transplant-related mortality than other published acute GVHD risk scores. Patients with HR-GVHD are
candidates for studies investigating new treatment approaches. Likewise, patients with SR-GVHD are can-
didates for studies investigating less toxic therapy.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
Acute graft-versus-host disease (GVHD) remains a major
cause of morbidity and mortality after hematopoietic cell
transplantation (HCT). Corticosteroids are the standarddgments on page 767.
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ty for Blood and Marrow Transplantation.initial therapy but are effective in only approximately half of
the cases [1,2]. Methods to identify patients who are unlikely
to respond to this conventional initial therapy and who
warrant alternative, more effective initial therapy are
needed. Earlier analyses have deﬁned high-risk (HR) acute
GVHD at time of onset by clinical stage and grade [2-5] and,
more recently, by serum biomarkers [6-8].
The Minnesota group recently deﬁned HR acute GVHD
by a novel acute GVHD risk score [9]. Initial high-risk (HR)
acute GVHD was deﬁned as either skin stage 4; lower
Table 1
Patient and Transplant Characteristics
Characteristic n (%)
Total no. patients 1723
Year of transplant
1990-1995 289 (17)
1996-2000 292 (17)
2001-2005 409 (24)
2006-2007 733 (43)
Age, yr
<20 421 (24)
21-40 459 (27)
41þ 843 (49)
Median (range) 40 (.2-76)
Gender
Male 1067 (62)
Female 656 (38)
Disease
Acute leukemia 741 (43)
CML 217 (13)
CLL/other leukemia 73 (4)
MDS/MPN 194 (11)
HL/NHL 236 (14)
Other malignancies 69 (4)
SAA/FA 81 (5)
Immune deﬁciency/hemoglobinopathy 28 (2)
Inborn error of metabolism 28 (2)
Disease risk*
Standard 816 (47)
High 907 (53)
Donor type
Matched Sibling BM/PBSC 598 (35)
Mismatched Related Donor BM/PBSC 73 (4)
Matched URD BM/PBSC 626 (36)
Mismatched URD BM/PBSC 164 (10)
Single or double UCB 262 (15)
Conditioning
Myeloablative 1273 (74)
Reduced intensity 450 (26)
CML indicates chronic myelogenous leukemia; CLL, chronic lymphocytic
leukemia; MDS, myelodysplastic syndrome; MPN, myeloproliferative
neoplasm; HL, Hodgkin lymphoma; NHL, non-Hodgkin lymphoma; SAA,
severe aplastic anemia; FA, Fanconi anemia; UCB, umbilical cord blood.
* Standard risk deﬁned as acute leukemia in CR1 or CR2, CML in ﬁrst
chronic phase, MDS without excess blasts or non-malignant diseases. All
others were high risk.
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3þ and either lower GI 2-4 or liver stage 2-4 GVHD. Patients
with this HR-GVHD were less likely to respond to steroid
therapy and had a 2-fold increased risk of treatment-related
(non-relapse) mortality (TRM) compared with patients with
standard-risk(SR)-GVHD. In order to validate this new GVHD
risk score, we examined a larger, heterogeneous group of
patients who received steroids as initial systemic therapy for
acute GVHD. A database of 1723 patients was created from 5
cohorts: the previously reported patients from the University
of Minnesota (n ¼ 864) [9], Blood and Marrow Transplant
Clinical Trials Network (BMT CTN) study 0302 (n ¼ 155) [10],
BMT CTN study 0802 (n¼ 213) [11], Hôpital Saint Louis, Paris
(n ¼ 184), and the University of Michigan (n ¼ 307). Patients
from Minnesota or Michigan enrolled in the BMT CTN trials
(n ¼ 33) were counted only once. The distribution of initial
GVHD organ staging combinations and subsequent re-
sponses to therapy were analyzed to predict responses and
deﬁne HR- and SR-GVHD.
PATIENTS AND METHODS
Study Design
Between 1990 and 2007, 1723 allogeneic HCT patients developed grade
I-IV acute GVHD and were treated with prednisone 2 mg/kg/day or 60 mg/
m2 per oral (or methylprednisolone 48 mg/m2 i.v.) as initial therapy and are
included in this analysis. All HCT and data collection protocols were
reviewed and approved by the Institutional Review Boards at the respective
HCT centers. Deidentiﬁed data were compiled for analysis.
Patient and Transplant Characteristics
Patient demographics including year of transplant, recipient age,
gender, cytomegalovirus (CMV) serostatus, and underlying diagnosis are
shown in Table 1. Median patient age was 40 years (range, 0.2 - 76) and 24%
were < 20 years of age. Standard risk disease was deﬁned as acute leukemia
in ﬁrst or second complete remission, chronic myelogenous leukemia (CML)
in ﬁrst chronic phase, or myelodysplastic syndrome (MDS) without excess
blasts. All other diseases were considered high risk.
Transplant characteristics including donor type and preparative therapy
are shown in Table 1. Graft sources included HLA-identical sibling bone
marrow (BM) or peripheral blood stem cells (PBSC; n ¼ 598), HLA-mis-
matched related donor BM or PBSC, (n¼ 73), HLA-matched unrelated donor
(URD) BM or PBSC (n ¼ 626), HLA-mismatched URD BM or PBSC (n ¼ 164),
single or double umbilical cord blood (UCB) (n ¼ 262). The majority (74%) of
patients received myeloablative conditioning regimens.
GVHD Therapy and Measurement of Response to Prednisone
All patients received prednisone at approximately 2mg/kg or 60mg/m2/
day per oral (or methylprednisolone i.v. equivalent) as initial therapy, and
353 (20%) received additional agents for initial treatment. Patients enrolled
in the BMT CTN 0302 trial received steroids and 1 of 4 additional agents
(etanercept, mycophenolate mofetil, denileukin diftitox, or pentostatin)
[10]. Those enrolled in the BMT CTN 0802 trial received steroids with
mycophenolate mofetil or placebo [11].
Response was determined comparing the initial acute GVHD stage and
grade in each organ to the best recorded stage and grade at day 28 (7 days)
after prednisone treatment was started. Complete response (CR) was
deﬁned as the complete resolution of acute GVHD manifestations in all or-
gans, without need for secondary GVHD therapy. Partial response (PR) was
deﬁned as improvement in GVHD stage in all initially affected organs,
without resolution in all organs, worsening in any other GVHD target organs,
or need for secondary GVHD therapy. No response was deﬁned as the same
severity of GVHD in any organ or death, or the addition of secondary GVHD
therapy before day 28. Patients who experienced a ﬂare of acute GVHD
before day 28 and required therapy with increased steroids or additional
GVHD therapy were also considered to have no response. Progression was
deﬁned as worsening GVHD in at least 1 organ with or without improve-
ment in any other organ.
Statistical Analysis
Simple proportions with 95% conﬁdence intervals were used to estimate
the rate of overall response deﬁned as CRþPR or CR alone. Survival after
GVHD treatment was analyzed by Kaplan-Meier estimates [12]. Non-
relapse, treatment-related mortality (TRM) was analyzed using cumulative
incidence estimates, treating relapse of the underlying HCT diagnosis as acompeting risk [13]. Outcomes were evaluated with the log-rank test for
trend or the simple log-rank test when comparing 2 categories.
Logistic regression was used to examine the independent association of
factors with CRþPR and CR alone at day 28 after onset of GVHD. Cox
regression was used to assess the independent association of the high- and
standard-risk categories with the probability of 6-month overall survival
[14], and Fine and Gray proportional hazards regression was used to assess
the independent association of the categories with risks of TRM and chronic
GVHD [15]. Clinical groupings, probabilities within organ staging categories,
and recursive partitioning were used to identify the optimal cut-point
among initial acute GVHD stage groupings for response at day 28 [16]. The
net reclassiﬁcation index (NRI), deﬁned as the net proportion of events
assigned to a higher risk category plus the net proportion of nonevents
assigned to a lower risk category, was used to assess and quantify the net
improvement in risk prediction by our reﬁned acute GVHD risk determi-
nation as compared to our original GVHD risk score [17] or other GVHD
grading schemes [2,9,18,19].
RESULTS
The median time from HCT to initiation of steroid therapy
was 30 days (range, 2 to 178; interquartile range, 21 to 43).
All patients had at least 3 months follow-up from GVHD
treatment (median, 4.9 years; range .3 to 17.7).
The initial GVHD stage in each organ is shown in Table 2.
Initial GVHD organ involvement was skin only (n ¼ 910;
53%), upper and/or lower GI only (n ¼ 346; 20%), liver only
(n¼ 23; 1%), or multi-organ (n¼ 556; 25%). Overall response
Table 2
GVHD Organ Stage and Clinical Grade in 1723 Patients at Onset of Treatment
Organ Stage 0 1 2 3 4
Skin 400 (23%) 262 (15%) 409 (24%) 639 (37%) 13 (1%)
Liver 1579 (92%) 57 (3%) 52 (3%) 25 (1%) 10 (1%)
Lower GI 1197 (69%) 262 (15%) 122 (7%) 122 (7%) 20 (1%)
Upper GI 1263 (73%) 460 (27)
Initial CIBMTR Grade
Initial MN Grade A B C D
I 146 280 0 0
II 0 383 570 0
III 0 121 183 7
IV 0 0 0 33
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(64%; 95% conﬁdence interval [CI], 62% to 66%). CR was
observed in 843 (49%, 95% CI, 47% to 51%) patients and PR in
268 (15%, 95% CI, 13% to 17%). For the entire cohort of 1723
patients, survival at 6 months after initiation of steroid
therapy was 68% (95% CI, 66% to 70%) and TRM at 6 months
was 26% (95% CI, 23% to 28%).
Initial GVHD grades by the Minnesota (MN) [2,9] and
Center for International Blood and Marrow Transplant
Research (CIBMTR) grading systems [19] at the initiation of
steroid therapy are shown in Table 2. The day 28 CR/PR rate
was 67% among patients with CIBMTR grades A and B GVHD
and 61% among those with grades C and D GVHD (P ¼ .008).
The day 28 CR/PR rate was 68% among patients with MN
grades I and II GVHD and 50% among those with grades III
and IV GVHD (P < .001).MN Acute GVHD Risk Score
According to a novel, previously published MN score that
combined the MN and CIBMTR grading systems [9], 146 (8%)
patients were classiﬁed as IA, 280 (16%) IB, 383 (22%) IIB, 570
(33%) IIC, 121 (7%) IIIB, 183 (11%) IIIC, 7 (<1%) IIID, and 33 (2%)Table 3
GVHD Organ Staging Categories
GVHD Categories Grouped
by Day 28 CR/PR
n Day 28
CR/PR
OR of Day 28
CR/PR (95% CI)
1. Stage 1-3 skin onlyy 901 68% 1.0
2. UGI only 115 78% 1.6 (1.0-2.6)
3. Stage 1-2 lower GI only 100 73% 1.3 (.8-2.1)
4. Stage 1-3 skin þ UGI 90 69% 1.0 (.6-1.6)
5. Stage 1-3 skin þ stage 1 Lower GI 71 61% .7 (.4-1.2)
6. Stage 1 lower GI þ upper GI 64 64% .8 (.5-1.4)
7. Stage 1-3 skin þ stage 1-4 liver 51 71% 1.1 (.6-2.1)
8. Stage 1-3 skin þ stage 1 lower
GI þ upper GI
62 61% .6 (.4-.9)
9. Stage 1-2 lower GI þ stage 1-3 liver 12 50% .4 (.1-1.4)
10. Stage 1-3 skin þ (stage 1-2 lower GI or
upper GI) þ stage 1-3 liver
23 35% .2 (.1-.6)
11. Stage 3 lower GI only 65 55% .5 (.3-.9)
12. Stage 1-3 skin þ stage 2 lower GI 54 52% .5 (.3-.9)
13. Stage 3-4 lower GI þ (stage 1-3 skin or
liver stage 1-4)
55 36% .2 (.1-.4)
14. Stage 1-4 liver alone 25 48% .3 (.2-.8)
15. Stage 1-3 skin þ stage 3-4 lower
GI þ stage 1-4 liver
13 8% .1 (.01-.3)
16. Stage 4 skin only 13 38% .3 (.1-.8)
17. Stage 4 lower GI only 22 22% .1 (.03-.7)
SR indicates standard risk; HR, high risk, UGI, upper gastrointestinal.
* SR and HR categories assigned by recursive partitioning for all 3 endpoints.
y Reference group; regression analysis includes adjustment for donor type [HLA-m
matched URD versus HLA-mismatched URD], days to acute GVHD (<28 days versus
0802 versus Paris versus Michigan), age (<21 versus 21-40 versus 41þ).IVD GVHD. This classiﬁcation was used to categorize SR and
HR groups. The day 28 CR/PR rate was 67% among 1500 pa-
tients with SR-GVHD (initial grade IA-IIIB) and 46% among
223 patients with HR-GVHD (initial grade IIIC-IVD) (P <
.001). In multivariate analysis, factors associated with CR/PR
at day 28 after starting steroid treatment included GVHD risk
group, donor type, and organ involvement, but not patient
age. Additionally, factors associated with a higher likelihood
of survival and lower TRM at 6 months included GVHD risk
group, younger patient age, disease risk, donor type, and
earlier onset of acute GVHD.
GVHD Organ Stage and Outcomes
Recognizing this heterogeneity in GVHD grading, partic-
ularly within clinical grades II and III, we then examined the
details of initial GVHD organ stage combinations to deter-
mine whether stage groupings would better identify the
patients at highest risk. We studied the 1723 patients and
divided them into 67 categories by organ stage and, thus,
extent of GVHD involvement at onset (Supplemental
Table 1). We collapsed these categories into 17 larger cate-
gories clustered as clinically similar cohorts with comparable
CR/PR at day 28, and we evaluated these new GVHD staging
categories for CR/PR, survival, and TRM (Table 3). We found a
clear demarcation between categories according to the CR/
PR rate at day 28 and risk of 6-month mortality and TRM,
thus dividing the cohort into SR-GVHD and HR-GVHD
groups.
Reﬁned Acute GVHD Risk Score
This reﬁned deﬁnition of SR-GVHD includes single organ
involvement (either stage 1-3 skin or stage 1-2 GI) or 2 organ
involvement (either stage 1-3 skin plus stage 1 GI; or stage
1-3 skin plus stage 1-4 liver). All other patients are consid-
ered HR. Table 4 describes the stage and organ involvement
(and subgroup frequency) by risk group for the patients in
this analysis. The day 28 CR/PR rate was lower in theP
Value
Relative Risk of
Mortality (95% CI)
P
Value
Relative Risk of
TRM (95% CI)
P
Value
GVHD
Risk*
1.0 1.0 SR
.04 .6 (.4-.9) .02 .5 (.3-.9) .03 SR
.29 1.2 (.8-1.7) .41 1.6 (1.0-2.3) .04 SR
.89 .9 (.6-1.4) .64 .9 (.6-1.5) .71 SR
.16 1.1 (.7-1.8) .60 1.3 (.8-2.1) .35 SR
.42 1.2 (.7-1.9) .54 1.4 (.9-2.4) .18 SR
.71 1.3 (.8-2.0) .30 1.4 (.9-2.3) .17 SR
.12 .6 (.3-1.1) .11 .6 (.3-1.3) .18 SR
.15 2.9 (1.4-6.3) .005 3.2 (1.5-7.0) .003 HR
.001 3.0 (1.7-5.1) <.001 3.2 (1.8-5.6) <.001 HR
.02 2.1 (1.4-3.1) .003 2.7 (1.8-4.2) <.001 HR
.01 1.5 (1.0-2.3) .08 1.6 (1.0-2.6) .06 HR
<.001 2.5 (1.7-3.6) <.001 3.0 (2.0-4.5) <.001 HR
.01 1.0 (.5-2.3) .96 1.7 (.8-3.8) .19 HR
.002 4.3 (2.3-8.2) <.001 7.4 (3.6-15.2) <.001 HR
.02 .8 (.2-3.1) .71 2.2 (.7-6.9) .16 HR
.02 3.5 (1.5-7.9) .003 3.1 (1.2-8.1) .02 HR
atched sibling versus other related versus umbilical cord blood versus HLA-
 28 days), center/dataset (Minnesota versus BMTCTN 0302 versus BMTCTN
Table 4
GVHD Risk Deﬁnition by Organ Stage at Onset
GVHD Risk Score One Organ (n) Two Organs (n) Three Organs (n)
SR (n ¼ 1454, 84%) Stage 1-3 Skin (901)
Stage 1-2 GI (279)y
Stage 1-3 skin plus stage 1 GI (223)*
Stage 1-3 skin plus stage 1-4 liver (51)
e
e
HRz (n ¼ 269, 16%) Stage 4 Skin (13)
Stage 3-4 GI (74)x
Stage 1-4 Liver (25)k
Stage 1-3 skin plus stage 2 GI (54)
Stage 1-2 lower GI plus stage 1-3 liver (12)
Stage 3-4 GI plus stage 1-3 skin (45)
Stage 3-4 GI plus stage 1-4 liver (10)
Stage 1-3 skin plus stage 1-2 GI plus
stage 1-3 liver (23)
Stage 1-3 skin plus stage 3-4 GI plus
stage 1-4 liver (13)
UGI plus lower GI considered as single-organ disease.
* Stage 1-3 skin plus stage 1 GI includes stage 1-3 skin plus UGI (n ¼ 90), stage 1-3 skin plus stage 1 lower GI (n ¼ 71), or stage 1-3 skin plus UGI plus stage 1
lower GI (n ¼ 62).
y Stage 1-2 GI includes UGI alone (n ¼ 115), stage 1-2 lower GI alone (n ¼ 100), or UGI or stage 1 lower GI (n ¼ 64).
z For HR disease, the degree of organ involvement is the minimum necessary to be deemed HR. Patients with higher stage of GVHD than observed in the HR
group should also be considered HR.
x Stage 3-4 GI includes stage 3 lower GI alone (n ¼ 65), or stage 4 lower GI alone (n ¼ 9).
k Stage 1-4 liver includes Stage 1 liver alone (n ¼ 7), stage 2 liver alone (n ¼ 10), stage 3 liver alone (n ¼ 5), or stage 4 liver alone (n ¼ 3).
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SR-GVHD (44% [95% CI, 38% to 50%] versus 68% [95% CI, 66%
to 70%], P < .001) (Figure 1). At day 28, the CR rates in HR-
GVHD and SR-GVHD cohorts were 27% (95% CI, 22% to 33%)
and 48% (95% CI, 45% to 51%); PR rates were 16% (95% CI, 12%
to 21%) and 21% (95% CI, 19% to 23%). Additionally, the 6-
month incidence of TRM was twice as high in patients with
HR-GVHD than in those with SR-GVHD (44% [95% CI, 38% to
50%] versus 22% [95% CI, 20% to 24%], P < .001) (Figure 2).
Finally, survival at 6 months after the onset of steroid treat-
ment was lower in patients with HR-GVHD than in those
with SR-GVHD (52% [95% CI, 46% to 58%] versus 71% [95% CI,
69% to 73%], P < .001).
In multiple regression analysis adjusted for clinically
signiﬁcant variables in addition to the risk group, the prob-
ability of CR/PR at day 28 in patients with HR-GVHD was
lower than in those with SR-GVHD (odds ratio [OR], .3; 95%
CI, .2 to .4; P < .001) (Table 5). Donor type was the only other
factor associated with response. Patients who received a
graft from an HLA-matched (OR, .7; 95% CI, .6 to .9; P¼ .01) or
mismatched URD (OR, .3; 95% CI, .2 to .5; P < .001) were less
likely to respond than those who received either a related
donor or umbilical cord blood graft. The number of days from
HCT to GVHD onset, patient age, original center/study cohort,
and other factors showed no statistically signiﬁcantly asso-
ciation with response.48%
27%
21%
16%
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Figure 1. Day 28 response by risk group. CR, complete response; PR, partial
response.In multivariate analysis, factors associated with CR/PR
were also associated with 6-month survival and TRM. These
included patient age, disease risk, donor type, time to onset
of acute GVHD, and the new, reﬁned GVHD risk group.
Patients with HR-GVHD had a 2-fold increase in risk of
mortality (relative risk, 2.1; 95% CI, 1.7 to 2.6; P < .001) and a
2.5-increased risk of TRM (relative risk, 2.5; 95% CI, 2.0 to 3.2;
P < .001) compared with patients with SR-GVHD. Risks of
mortality and TRM were also signiﬁcantly higher in older
patients, recipients of HLA-matched or mismatched URD
grafts, and in those with onset of GVHD within 28 days after
HCT (Table 5).
The reﬁned GVHD risk score more effectively re-
distributes patients based on their predicted outcomes
compared with the original GVHD risk score and the CIBMTR
or the MN grading systems (Table 6). Seventy-six of 1500
(5%) SR patients in the original scoring system, 72 of 930 (8%)
patients with CIBMTR grades A-B, and 14 (1%) of the 1379
patients with MN I-II GVHD were reclassiﬁed as HR accord-
ing to this reﬁned scoring system. More strikingly, 30 of 223
(13%) HR patients from the original scoring system, 596 of
793 (75%) patients with CIBMTR grades C-D, and 89 of 344
(26%) of MN grade III-IV were reclassiﬁed as SR according to
this reﬁned scoring system.
As shown in Table 7, the reﬁned GVHD risk score better
demarcates day 28 CR/PR (SR 68% versus HR 44%, P < .001)
compared with our initial GVHD risk score (SR 67% versus
HR 46%, P < .001), CIBMTR grading system (A-B 67% versus
C-D 61%, P¼ .008), or the MNGVHD grading system (I-II 68%
versus III-IV 50%, P < .001). Similarly, our new reﬁned risk
classiﬁcation better predicts 6-month survival (SR 71%Months after Initiation of Steroid GVHD Therapy
High risk: 44% (38-50%)
Pr
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Figure 2. Cumulative incidence (95% CI) of TRM at 6 months after onset of
steroid therapy according to risk group.
Table 5
Factors Associated with Day 28 CR/PR, 6 Month Mortality and TRM: Multivariate Analysis
Factors n OR of Day 28
CR/PR (95% CI)
P Value Relative Risk of
Mortality (95% CI)
P Value Relative Risk of
TRM (95% CI)
P Value
Age
<20* 421 1.0 1.0 1.0
21-40y 459 .8 (.6-1.1) .10 1.3 (1.0-1.8) .03 1.6 (1.2-2.1) .004
41þ 843 .8 (.6-1.1) .15 1.7 (1.3-2.3) <.001 2.4 (1.8-3.3) <.001
Disease riskz
Standard* 812 1.0 1.0 1.0
High 717 1.1 (.9-1.4) .45 1.2 (1.0-1.5) .05 1.1 (.9-1.3) .52
Nonmalignant 191 .9 (.6-1.3) .47 1.06 (.8-1.5) .74 1.8 (1.3-2.5) .001
Conditioning regimen
Myeloablative* 1273 1.0 1.0 1.0
Reduced intensity 450 1.2 (.9-1.6) .24 1.0 (.8-1.2) .78 .9 (.6-1.1) .25
Donor type
Matched sibling* 598 1.0 1.0 1.0
Other related 73 .9 (.5-1.5) .62 1.5 (1.0-2.2) .07 1.6 (1.0-2.6) .42
Matched URD 626 .7 (.6-.9) .01 1.5 (1.2-1.8) <.001 1.6 (1.2-2.0) <.001
Mismatched URD 164 .3 (.2-.5) <.001 2.2 (1.6-2.9) <.001 2.4 (1.7-3.2) <.001
UCB 262 .9 (.7-1.3) .45 1.1 (.8-1.4) .67 1.0 (.7-1.4) .81
Days from HCT to initial steroid
treatment
<28 days* 717 1.0 1.0 1.0
28 days 1006 1.2 (1.0-1.5) .06 .8 (.7-.9) .006 .8 (.7-1.0) .02
GVHD riskx
SR* 1454 1.0 1.0 1.0
HR 269 .3 (.2-.4) <.001 2.1 (1.7-2.6) <.001 2.5 (2.0-3.2) <.001
Bold indicates statistical signiﬁcance.
* Reference group.
y Comparison of 21-40 versus 41þ: for CR/PR, P ¼ .27; for mortality, P ¼ .02; for TRM, P < .001.
z Standard-risk includes acute leukemia in CR1 or CR2, CML in ﬁrst chronic phase, MDS without excess blasts, or non-malignant disease. High risk includes all
others.
x As deﬁned in Table 3with SR including organ involvement (stage 1-3 skin or stage 1-2 GI) or 2 organ involvement (stage 1-3 skin plus stage 1 GI; or stage 1-3
skin plus stage 1-4 liver). All other patients are HR.
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risk score (SR 70% versus HR 54%, P < .001), the CIBMTR
grading system (A-B 71% versus C-D 65%, P ¼ .008) or the
MN grading system (grade I-II 71% versus grade III-IV 56%, P
< .001). TRM at 6 months was similar using this reﬁned risk
score (SR 22% versus HR 43%, P < .001) and the original
GVHD risk score (SR 23% versus HR 42%, P< .001), but is better
delineated than with the CIBMTR grading system (A-B
23% versus C-D: 29%, P ¼ .006) or the MN grading system
(grade I-II 22% versus grade III-IV 40%, P < .001). As measured
by the NRI, our reﬁned deﬁnition of GVHD improves both the
true-positive and false-positive rates among our study popu-
lation. The net percentage of patients more appropriately
reclassiﬁed both in the positive and negative direction (eg,
response and no response) is 5% (P< .001) for response and 4%
for 6-month survival (P < .001) compared with our original
deﬁnition of GVHD risk. Importantly, the NRI is 6% (P < .001)
for response, 4% for 6-month survival (P ¼ .002) and 5% for 6-
month TRM (P < .001) compared to the MN grading system
and is a better discriminant of outcome for all endpoints than
the NRI of our original GVHD risk score and MN grading
system.Table 6
GVHD Risk Classiﬁcation by Different Scoring Systems
Reﬁned Acute
GVHD Risk Score
Original Acute GVHD
Risk Score [9]
CIBMTR Gradin
SR HR SR (A-B)
SR 1424 30 858
HR 76 193 72
Total 1500 (87%) 223 (13%) 930 (54%)DISCUSSION
In our previous analysis of GVHD scoring systems, we
observed that the heterogeneity of the CIBMTR grades B-C
(which include MN grades I-III) contributed to weak pre-
dictive utility for GVHD therapy outcomes [9]. We have,
therefore, derived a combined scoring system, which better
identiﬁed HR-GVHD patients who needmore intensive initial
therapy than prednisone alone [9]. To develop this reﬁned
GVHD risk score, we included independent data from 2
prospective BMT CTN trials as well as from 2 other large HCT
centers (Hôpital Saint Louis, Paris and the University of
Michigan). The reﬁned deﬁnition of SR and HR groups, based
upon initial GVHD stage, serves as a better predictor of
response and survival than either the previous risk score,
which was based upon initial GVHD grade [9], or the MN or
CIBMTR grading systems. Patients in the HR group were
much less likely to respond to initial steroid therapy and had
at least 2-fold increased risk of mortality and TRM than those
in the SR group. Outcomes are poor for patients with
HR-GVHD treated with steroids alone, and these patients
should be considered for enrollment in clinical trials testing
new approaches for treatment of acute GVHD. Conversely,g [20] MN Grading [18,19] n (%)
HR (C-D) SR (I-II) HR (III-IV)
596 1365 89 1454 (84%)
197 14 255 269 (16%)
793 (46%) 1379 (80%) 344 (20%)
Table 7
Outcomes Based on Published GVHD Grading Systems
GVHD Grading System n CR/PR at Day 28 P 6-Month Survival P 6-Month TRM P
CIBMTR
A-B 930 626 (67%) 660 (71%) 213 (23%)
C-D 793 485 (61%) .008 515 (65%) .008 228 (29%) .006
MN
I-II 1379 938 (68%) 984 (71%) 304 (22%)
III-IV 344 173 (50%) <.001 192 (56%) <.001 137 (40%) <.001
Original GVHD risk score
SR 1500 1008 (67%) 1055 (70%) 347 (23%)
HR 223 103 (46%) <.001 121 (54%) <.001 94 (42%) <.001
Reﬁned GVHD risk score
SR 1454 993 (68%) 1039 (71%) 326 (22%)
HR 269 118 (44%) <.001 137 (53%) <.001 115 (43%) <.001
Number changed from
SR- to HR-GVHD
Number changed from
HR- to SR-GVHD
% Reclassiﬁed P % Reclassiﬁed P % Reclassiﬁed P
NRI* (reﬁned versus original) 76 30 5% <.001 4% <.001 0% .21
NRI* (reﬁned versus MN) 14 89 6% <.001 4% .002 5% <.001
NRI* (reﬁned versus CIBMTR) 72 596 19% <.001 7% .001 14% <.001
NRI* (original versus MN) 0 121 1% .74 2% .02 4% .001
* Net reclassiﬁcation Index (NRI) deﬁned as the net percentage of patients more appropriately reclassiﬁed both in positive and negative direction (eg, response
and no response) [17]. The P value is comparing against the null hypothesis that there is no net beneﬁt.
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therapeutic approaches designed to limit risks of treatment
toxicity or risks of chronic GVHD.
Our reﬁned deﬁnition of GVHD risk is confounded by a
few small subsets of patients. Twenty-ﬁve (1%) patients with
stage 1-4 liver disease alonewere deemed HR-GVHD, as their
outcomes were universally poor. However, 51 (3%) patients
with stage 1-3 skin plus stage 1-4 liver had favorable out-
comes and were scored SR-GVHD. Although this discrepancy
cannot be fully explained, patients with liver only disease
consistently had poor outcomes and should still be consid-
ered as having high risk disease while raising questions
about the validity of their GVHD diagnoses compared with
nonrecognized alternative hepatic syndromes complicating
the diagnosis of liver only GVHD. Ten patients (<.5%) did not
easily ﬁt into any category, as shown in the Supplemental
Table 1, and were included within a clinically similar cate-
gory. Additionally, not all potential organ stage combinations
and permutations were observed in our cohort of 1723nikS 3-1 egatS
1-2
Stage 1-2 GI
One Organ
52% 16%
Figure 3. Organ stages deﬁning HR acute GVHD with pepatients. Given the poor outcomes of patients in the HR-
GVHD category, future patients presenting with higher
stage involvement than those observed should also be
considered high risk.
We chose 2 GVHD risk groups because when we exam-
ined CR/PR at day 28, as well as mortality and TRM, 2 groups
became apparent: a large group consisting of 84% of the
patients with similar outcomes and a smaller group
comprising 16% of the patients with far worse outcomes.
Within the large SR-GVHD group, there was no deﬁnable
staging cohort with better outcomes. For instance the CR/PR
rate of the 426 patients with stage 1-2 skin only GVHD (69%)
was the same as the 475 patients with stage 3 skin only
GVHD (67%). Therefore, although one might consider 3
groups to be more practical (ie, low, standard and high risk),
the data showed that there were 2 GVHD risk groups, not 3
or more.
We also chose to use the entire cohort for analysis rather
than divide into a training and validation set. Even in this nikS 3-1 egatS
plus Stage 1 GI 
Stage 1-3 Skin plus 
Stage 1-4 Liver 
1
Two Organs
1-4
13% 3%
rcentage involved of total cohort of 1723 patients.
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characteristics, some of the identiﬁed groups are small.
Subdivision of the population further would have either
missed these cohorts entirely or limited our ability to classify
them correctly. Future, independent analyses will thus
better be able to conﬁrm or reﬁne the utility of this new
classiﬁcation.
It is simple to deﬁne SR-GVHD in our cohort (Table 4;
Figure 3). These 84% patients were deﬁned by single organ
involvement (stage 1-3 skin or stage 1-2 GI) or 2 organ
involvement (stage 1-3 skin plus stage 1 GI; or stage 1-3 skin
plus stage 1-4 liver). Since our deﬁnition of HR-GVHD
includes 9 distinct subgroups, we more simply deﬁne
HR-GVHD as those who are not SR. These remaining 16% of
patients had HR-GVHD characterized as having either
severe single-organ involvement or complex multi-organ
GVHD. We designed a free web-based program to easily
determine the GVHD risk group for a given patient using
our reﬁned risk score, available at: http://z.umn.edu/
MNAcuteGVHDRiskScore.
As more than 25,000 people worldwide develop acute
GVHD annually, our new scoring system would reclassify
20,750 cases (83%) if the CIBMTR grading were used and
6750 (27%) if MN grading system were used, allowing for
more appropriate therapy upfront. Biomarkers have been
recently studied as a means to identify HR-GVHD patients,
but their prognostic capability varies and no validated
biomarker test is currently available for real-time decision
making [6-8,21]. By contrast, this new revised clinical scoring
system is available to clinicians at the bedside in real time. A
future prospective study to examine this GVHD score along
with informative biomarkers in the same GVHD population
could help further reﬁne the prognostic capability of each
and determine whether a combination of clinical score and
biomarker levels could even better identify HR-GVHD.
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